Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Ramucirumab in Advanced Gastric/GEJ Adenocarcinoma
NCT04675983Phase 3Terminated
- Sponsor
- Innovent Biologics
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Overall Survival up to 60 months and Safety and tolerability up to 60 months. Started Mar 2021; status: terminated.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04675983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675983.